(HealthDay)—Two new drugs have been approved by the U.S. Food and Drug Administration to treat progressive lung scarring from an uncertain cause, medically called idiopathic pulmonary fibrosis (IPF).
Despite claiming an estimated 40,000 lives annually - roughly the same number as breast cancer or prostate cancer - pulmonary fibrosis remains one of the least known covert killers in the country.
(AP)—The Food and Drug Administration has approved a new long-acting inhaler drug from Boehringer Ingelheim to treat people with chronic lung disease.
A medical journal raised concerns Wednesday about a blood-thinning drug widely used by people at risk of stroke, accusing its manufacturer of concealing safety data and regulators of laxness.
German pharmaceuticals maker Boehringer Ingelheim said Wednesday it has agreed to pay $650 million to settle around 4,000 lawsuits relating to its blood-thinning drug Pradaxa.
(HealthDay)—A single intravenous bolus of tenecteplase reduces early death and hemodynamic decompensation in normotensive patients with intermediate-risk pulmonary embolism, but increases the risk of major ...
The families of four elderly people who died while taking an anti-clotting drug have filed a legal complaint against France's drugs safety body and Germany-based drugmaker Boehringer Ingelheim, their lawyers said Wednesday.
(HealthDay)—Patients with heart valve replacements have greater rates of thromboembolic and bleeding complications after treatment with dabigatran compared with warfarin, according to a study published ...
Linagliptin (trade name Trajenta) has been approved since August 2011 to improve blood glucose control in adults with type 2 diabetes. The assessment of the new dossier according to the German Act on the Reform of the Market ...
(AP)—A panel of federal health experts is overwhelmingly recommending approval for a long-acting inhaler to treat people suffering from chronic lung disease.